

# Antonio Costanzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2249361/publications.pdf>

Version: 2024-02-01

97  
papers

5,716  
citations

87888

38  
h-index

76900

74  
g-index

98  
all docs

98  
docs citations

98  
times ranked

6453  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unmet needs in atopic dermatitis management: an expert consensus. Journal of Dermatological Treatment, 2022, 33, 2459-2465.	2.2	7
2	Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. Journal of Allergy and Clinical Immunology, 2022, 149, 977-987.e14.	2.9	66
3	Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination. Journal of Autoimmunity, 2022, 127, 102783.	6.5	36
4	What Can IBD Specialists Learn from IL-23 Trials in Dermatology?. Journal of Crohn's and Colitis, 2022, 16, ii20-ii29.	1.3	10
5	Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIdemaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Italian Journal of Dermatology and Venereology, 2022, 157, .	0.2	7
6	Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	21
7	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Italian Journal of Dermatology and Venereology, 2022, 157, 1-78.	0.2	25
8	Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study. Dermatologic Therapy, 2022, 35, e15253.	1.7	5
9	Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192-week multicentric retrospective study (IL PSO) (Italian landscape psoriasis). Dermatologic Therapy, 2022, 35, .	1.7	10
10	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2087-2100.	2.4	15
11	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: Northern Italy experience. Journal of Allergy and Clinical Immunology, 2021, 147, 558-560.e1.	2.9	44
12	Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 693-700.	2.4	26
13	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576.	1.3	5
14	Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis. European Journal of Dermatology, 2021, 31, 3-16.	0.6	10
15	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 2021, 157, 1047.	4.1	236
16	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy, 2021, 11, 235-252.	3.0	34
17	Physician-Scientists in Italian Dermatology: Hurdles and Perspectives. JID Innovations, 2021, 2, 100077.	2.4	0
18	The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. British Journal of Dermatology, 2020, 183, 373-374.	1.5	104

#	ARTICLE	IF	CITATIONS
19	TNF-Î± inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology, 2020, 16, 591-598.	3.0	18
20	Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 1-7.	0.8	18
21	Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 276-286.	3.3	43
22	Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Global & Regional Health Technology Assessment, 2019, 2019, 228424031882228.	0.1	2
23	Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. British Journal of Dermatology, 2019, 181, 413-414.	1.5	21
24	Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. Therapeutic Drug Monitoring, 2019, 41, 634-639.	2.0	8
25	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Advances in Therapy, 2018, 35, 545-562.	2.9	16
26	HLA -C*06 and psoriasis: susceptibility, phenotype, course and response to treatment. British Journal of Dermatology, 2018, 178, 825-825.	1.5	1
27	Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. British Journal of Dermatology, 2018, 179, 1072-1080.	1.5	44
28	Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. Dermatologic Therapy, 2018, 31, e12565.	1.7	4
29	Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. Dermatology, 2018, 234, 1-12.	2.1	22
30	Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA). Italian Journal of Dermatology and Venereology, 2018, 153, 133-145.	0.2	25
31	Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2017, 11, 203-214.	3.0	19
32	Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. British Journal of Dermatology, 2017, 177, 489-496.	1.5	55
33	Diagnostic imaging: Listening in to skin disease. Nature Biomedical Engineering, 2017, 1, .	22.5	2
34	Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders. International Journal of Psychiatry in Clinical Practice, 2017, 21, 209-214.	2.4	27
35	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of Dermatology, 2017, 76, 1093-1102.	1.2	110
36	Cutaneous and Mucosal Manifestations of Sjögren's Syndrome. Clinical Reviews in Allergy and Immunology, 2017, 53, 357-370.	6.5	47

#	ARTICLE	IF	CITATIONS
37	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1562-1574.	1.5	68
38	Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e128-e129.	2.4	6
39	Label-free and non-invasive discrimination of HaCaT and melanoma cells in a co-culture model by hyperspectral confocal reflectance microscopy. <i>Journal of Biophotonics</i> , 2016, 9, 619-625.	2.3	7
40	Professor Sergio Chimenti: 1949-2016. <i>British Journal of Dermatology</i> , 2016, 174, 1161-1162.	1.5	0
41	Psychiatric comorbidity and suicide risk in patients with psoriasis. <i>European Psychiatry</i> , 2016, 33, S395-S396.	0.2	1
42	IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis. <i>Dermatology</i> , 2016, 232, 230-236.	2.1	44
43	Suicide risk and psychiatric comorbidity in patients with psoriasis. <i>Journal of International Medical Research</i> , 2016, 44, 61-66.	1.0	46
44	Long-term safety of etanercept in psoriasis: Retrospective study focused on infections. <i>Journal of International Medical Research</i> , 2016, 44, 58-60.	1.0	0
45	Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1299-1308.	3.0	67
46	Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 141, 141-147.	5.0	104
47	HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 374-375.	1.2	40
48	Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , 2016, 25, 1179-1188.	3.1	16
49	Towards a targeted therapy for pyoderma gangrenosum. <i>British Journal of Dermatology</i> , 2015, 173, 1124-1124.	1.5	0
50	Programmed cell death in the skin. <i>International Journal of Developmental Biology</i> , 2015, 59, 73-78.	0.6	22
51	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015, 14, 864-874.	5.8	25
52	FGF8, c-Abl and p300 participate in a pathway that controls stability and function of the $\beta$ -casein protein. <i>Human Molecular Genetics</i> , 2015, 24, 4185-4197.	2.9	12
53	What Happened after the Clinical Trials: Long-Term Safety and Efficacy of Ustekinumab in Daily Clinical Practice. <i>Dermatology</i> , 2014, 229, 324-332.	2.1	14
54	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. <i>Nature Communications</i> , 2014, 5, 5621.	12.8	427

#	ARTICLE	IF	CITATIONS
55	DLX5, FGF8 and the Pin1 isomerase control $\hat{p}^{31}$ protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations. Human Molecular Genetics, 2014, 23, 3830-3842.	2.9	33
56	Detection of Adalimumab and Anti-Adalimumab Levels by ELISA: Clinical Considerations. Drug Development Research, 2014, 75, S11-S14.	2.9	8
57	<i>p53</i> and <i>p73</i> in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. FEBS Letters, 2014, 588, 2590-2599.	2.8	39
58	Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. Immunology Letters, 2013, 156, 127-131.	2.5	23
59	The Role of IL-21 in Chronic Inflammatory Skin Diseases. Current Dermatology Reports, 2013, 2, 11-17.	2.1	1
60	Pharmacogenetics of psoriasis: <i>HLA-Cw6</i> but not <i>LCE3B/3C</i> deletion nor <i>TNFAIP3</i> polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. British Journal of Dermatology, 2013, 169, 458-463.	1.5	134
61	Living Matter Observations with a Novel Hyperspectral Supercontinuum Confocal Microscope for VIS to Near-IR Reflectance Spectroscopy. Sensors, 2013, 13, 14523-14542.	3.8	12
62	HIPK2 phosphorylates $\hat{p}^{31}$ and promotes its degradation in response to DNA damage. Oncogene, 2011, 30, 4802-4813.	5.9	57
63	NF- $\hat{p}B$ , $\hat{p}B$ Kinase and Interacting Signal Networks in Squamous Cell Carcinomas. , 2011, , 201-222.		1
64	IL-21 in the pathogenesis and treatment of skin diseases. Journal of Dermatological Science, 2010, 60, 61-66.	1.9	34
65	Efficacy of Efalizumab in Psoriasis Patients Previously Treated with Tumour Necrosis Factor Blockers. Dermatology, 2009, 219, 48-53.	2.1	3
66	Efficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab Therapy. Dermatology, 2009, 218, 146-150.	2.1	11
67	Pathogenic role of interleukin-21 in psoriasis. Cell Cycle, 2009, 8, 3629-3630.	2.6	12
68	Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle, 2009, 8, 3396-3405.	2.6	16
69	Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Myeloma Cells Sensitive and Resistant to Bortezomib.. Blood, 2009, 114, 1837-1837.	1.4	0
70	RelA/NF- $\hat{p}B$ recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death and Differentiation, 2008, 15, 354-363.	11.2	39
71	Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy, 2008, 8, 363-370.	3.1	18
72	The tumor suppressor activity of IKK $\hat{1}$ in stratified epithelia is exerted in part via the TGF- $\hat{p}2$ antiproliferative pathway. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17091-17096.	7.1	59

#	ARTICLE	IF	CITATIONS
73	Regulation of <i>Dlx5</i> and <i>Dlx6</i> gene expression by p63 is involved in EEC and SHFM congenital limb defects. <i>Development (Cambridge)</i> , 2008, 135, 1377-1388.	2.5	109
74	Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1410-1419.	4.1	53
75	Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 269-275.	1.2	121
76	Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. <i>British Journal of Dermatology</i> , 2007, 156, 17-23.	1.5	31
77	Cross-Talks in the p53 Family: p63 is an Anti-Apoptotic Target for p73 and p53 Gain of Function Mutants. <i>Cell Cycle</i> , 2006, 5, 1996-2004.	2.6	40
78	A p38-dependent pathway regulates p63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes. <i>Oncogene</i> , 2005, 24, 6970-6975.	5.9	39
79	Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts. <i>Blood</i> , 2005, 106, 613-613.	1.4	0
80	CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF- $\kappa$ B subunits on IL-8 and Bcl-xL gene promoters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6098-6103.	7.1	75
81	Endothelial activation by angiotensin II through NF- $\kappa$ B and p38 pathways: Involvement of NF- $\kappa$ B-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. <i>Journal of Cellular Physiology</i> , 2003, 195, 402-410.	4.1	127
82	Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and healthy blood donors. <i>Digestive and Liver Disease</i> , 2002, 34, 570-576.	0.9	3
83	DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes. <i>Molecular Cell</i> , 2002, 9, 175-186.	9.7	298
84	DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. <i>Oncogene</i> , 2002, 21, 3796-3803.	5.9	75
85	Induction of gene expression via activator protein-1 in the ascorbate protection against UV-induced damage. <i>Biochemical Journal</i> , 2001, 356, 77-85.	3.7	61
86	The p53/p63/p73 family of transcription factors: overlapping and distinct functions. <i>Journal of Cell Science</i> , 2000, 113, 1661-1670.	2.0	467
87	The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. <i>Nature</i> , 1999, 399, 806-809.	27.8	863
88	Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants $\Delta\mu$ and $\Delta\eta$ . <i>Cell Death and Differentiation</i> , 1999, 6, 389-390.	11.2	151
89	Two New p73 Splice Variants, $\Delta^3$ and $\Delta^4$ , with Different Transcriptional Activity. <i>Journal of Experimental Medicine</i> , 1998, 188, 1763-1768.	8.5	361
90	Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. <i>Gastroenterology</i> , 1997, 113, 1384-1389.	1.3	68

#	ARTICLE	IF	CITATIONS
91	Infection of Circulating and Liver Infiltrating T Cells by Hepatitis C Virus of Different Subtypes. <i>Viral Immunology</i> , 1995, 8, 63-73.	1.3	14
92	Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 1995, 2, 33-38.	2.0	62
93	Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX.. <i>Molecular and Cellular Biology</i> , 1994, 14, 989-998.	2.3	146
94	Characterization of the hepatitis B virus transactivators: A possible direct role of the virus in the development of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 34-36.	1.7	1
95	Label-free discrimination of cells undergoing apoptosis by hyperspectral confocal reflectance imaging. <i>Journal of the European Optical Society-Rapid Publications</i> , 0, 8, .	1.9	6
96	DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. , 0, .		2
97	Project R. Evolution for improving clinical research in Italy: challenges and strategies. <i>Current Medical Research and Opinion</i> , 0, , 1-9.	1.9	0